CJC1295

All articles and product details on this website are provided solely for informational and educational purposes. Our products are not drugs and have not been evaluated or approved by the FDA to diagnose, treat, prevent, or cure any disease or medical condition. These materials are intended exclusively for laboratory research use. Any form of human or animal consumption, application, or bodily introduction is strictly prohibited by law.

Objective

To identify biomarkers of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) action in human serum.

Background

The search for new markers of GH activity has received extensive attention given that the current biomarkers (IGF-1, IGFBP-3 and collagen peptides) show substantial variability in the population, and are not reliably predictive of either the physiologic effects of GH therapy or the detection of GH abuse by athletes. GH releasing hormone (GHRH) is a polypeptide synthesized in the hypothalamus that binds to receptors on pituitary somatotropes to promote the synthesis and release of GH. Serum GH and IGF-1 levels have been shown to increase with administration of GHRH or CJC-1295, a long acting GHRH analog.

Design

Sera from 11 healthy young adult men before and one week after CJC-1295 injection were analyzed by two-dimensional gel electrophoresis for proteomic changes. Serum proteins displaying significant changes before and after treatment were subsequently identified using mass spectrometry. In addition, correlations between these proteins and GH or IGF-1 levels were evaluated.

Results

Two protein spots that displayed decreased intensities after treatment were identified as an apolipoprotein A1 isoform and a transthyretin isoform. Three protein spots upregulated by CJC-1295 treatment included beta-hemoglobin, a C-terminal fragment of albumin, and a mix of an immunoglobulin fragment and another C-terminal albumin fragment. A linear relationship was found between the spot containing immunoglobulin and albumin fragments and IGF-1 levels.

Conclusions

Although the molecular mechanisms linking the identified proteins to GH and IGF-1 biological activity remain to be clarified, the results suggest that they represent potential biomarkers of GH and/or IGF-1 action.

More details on original article click here

Original author:

Department of Biological Sciences, Ohio University, Athens, Ohio, United States, 45701
2Molecular and Cellular Biology Program, Ohio University, Athens, Ohio, United States, 45701
3Department of Biomedical Sciences, Ohio University, Athens, Ohio, United States, 45701
4Edison Biotechnology Institute, Ohio University, Athens, Ohio, United States, 45701
5Section of Endocrinology, Diabetes, and Metabolism, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, United States, 60608
✉

Corresponding author: John J. Kopchick, PhD., Edison Biotechnology Institute, Ohio University, 101 Konneker Research Laboratories, The Ridges, Athens, Ohio 45701, Tel: (740) 593-4534, Fax: (740) 593-4975, E-mail: kopchick@ohio.edu

PMCID: PMC2787983  NIHMSID: NIHMS102981  PMID: 19386527

 

Research Use Only
All products offered by VYNT Peptides are intended strictly for laboratory research. They are not intended for human consumption, medical use, therapeutic use, or diagnostic procedures. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease. VYNT is a chemical supplier.

VYNT is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. VYNT is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.

 

No Medical Claims
VYNT Peptides makes no claims that any product can diagnose, treat, cure, or prevent any disease.

 

Age & Qualification Requirement
Purchasers must be 18+ and qualified to safely handle laboratory research materials.